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ABSTRACT
In 2008 isolates of KPC-producing Klebsiella pneumoniae (KPC-KPN) were detected for the fi rst 
time at Hospital Heliópolis, São Paulo, Brazil. The aim of this study was to characterize the clinical 
and microbiological outcomes of infections caused by KPC-KPN. A historical cohort of patients 
from whom KPC-KPN strains were isolated was performed. Isolates were identifi ed as resistant 
to ertapenem by automated broth microdilution system and screened as carbapenemase produc-
ers by the modifi ed Hodge test. The beta-lactamase resistance gene blaKPC was detected by PCR. 
The genetic relatedness of isolates was determined by PFGE. The study provides early clinical experi-
ence in treating KPC-KPN infections in a Brazilian tertiary center.
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INTRODUCTION
Carbapenems such as imipenem and meropen-
em are recommended as fi rst-line therapy for 
severe infections caused by Enterobacteriaceae 
producing extended spectrum β-lactamases 
(ESBLs).1 The increasing incidence of Klebsiella 
pneumoniae carbapenemase (KPC)-producing 
strains worldwide has posed a challenge for 
diagnosing and treating such infections since 
these isolates might be phenotypically detected 
as susceptible to carbapenems.2 In addition, 
therapeutic options for the treatment of these 
infections are basically restricted to tigecycline 
and polymyxins. However, the clinical use of 
these antimicrobials has been limited due to 
their pharmacokinetics properties and toxicity. 
Moreover, no new antibiotics against these mul-
tidrug-resistant (MDR) organisms are in ad-
vanced stages of clinical development (Table 1).3
KPC-producing Klebsiella pneumoniae 
(KPC-KPN) was fi rst isolated in North Caro-
lina in 1996.4 It remained infrequently isolated 
until 2001, when several outbreaks occurred in 
hospitals located in the New York region.5 KPC-
KPN has spread over time in many countries 
around the world, and have been frequently iso-
lated from Israel,6 China7 and Greece.8 In South 
America, the fi rst detection of a KPC-2-pro-
ducing Klebsiella pneumoniae isolates occurred 
in Colombia9 in 2006. Although the KPC-KPN 
isolates were detected in the cities of Recife and 
Rio de Janeiro, in 2006 and 2007, respectively,10,11 
an early dissemination of KPC-KPN in the Bra-
zilian territory was reported by Pavez et al. These 
authors showed that KPC-KPN was detected in 
the city of São Paulo, in 2005.12 In 2008, we de-
tected for the fi rst time isolates of K. pneumoniae 
resistant to ertapenem in the Hospital Heliópolis, 
a teaching tertiary hospital located in the city of 
São Paulo, Brazil. These isolates were identifi ed 
as resistant to ertapenem by automated broth 
microdilution system (MicroScan; Siemens) 
and screened as carbapenemase producers by 
the modifi ed Hodge test as recommended 
by the Clinical Laboratory Standards Institute 
(CLSI, 2009). These isolates were referred to 
Laboratório Alerta, Division of Infectious Dis-
eases, UNIFESP/EPM, where antimicrobial sus-
ceptibility testing, KPC production and genetic 
relatedness among KPC-KPN isolates were per-
formed by CLSI agar dilution, PCR and PFGE, 
respectively.
We sought to study the clinical and micro-
biological outcomes of the KPC-KPN infec-
tions by performing a historical cohort of pa-
tients from whom KPC-KPN strains had been 
isolated. Medical records of colonized/infected 
KPC-KPN patients were reviewed. Success or 
failure of treatment was determined by clinical 
response. This study was approved by the insti-
tutional review board. 
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Characterization of KPC in Brazil
Six KPC-KPN were isolated from six distinct patients 
between May 2008 and February 2009. Patient’s age ranged 
from 54 to 89 years. Most patients (66.6%) had been hospi-
talized for at least three weeks before KPC-KPN isolation. 
Beta-lactams (50%) were the most common antimicrobial 
therapy prior to KPC-KPN isolation, with a single patient 
receiving carbapenem therapy. 
The susceptibility profi le of the KPC-KPN isolates is 
shown in Table 2. Of the six KPC-KPN cultured from inpa-
tients, three (50%) were originally reported as imipenem sus-
ceptible. Phenotypic detection of carbapenemase production 
was reported only three days later. All KPC-KPN exhibited 
resistance to beta-lactam/beta-lactamase inhibitor combina-
tion, carbapenems, and third-generation cefalosporins, ex-
cept for a single isolate that showed susceptibility to ceftazi-
dime and ceftriaxone. In contrast, all KPC-KPN isolates were 
susceptible to amikacin. No full resistance to tigecycline or 
polymyxin B was observed among the CRKP tested. 
Table 2. MIC of selected antimicrobial agents for KPC-KPN strains
            Patient and MIC(µg/mL)
Antibiotic  1  2  3  4  5  6 
Amikacin  8  < 4  < 4  < 4  < 4  8 
Polymyxin B  < 0.5  < 0.5  < 0.5  4  < 0.5  2 
Ciprofloxacin > 2 < 0.25 > 2 > 2 > 2 > 2
Levofloxacin > 4 2 > 4 > 4 > 4 > 4
Aztreonam > 16 > 16 > 16 > 16 > 16 > 16
Cefoxitin > 16 8 > 16 > 16 > 16 > 16
Tigecycline 1 0.5 4 2 2 2
Ceftriaxone > 32 8 > 32 > 32 > 32 > 32
Ceftazidime > 16 8 > 16 > 16 > 16 > 16
Cefepime > 16 > 16 > 16 > 16 > 16 > 16
Imipenem > 8 > 8 > 8 > 8 > 8 > 8
Meropenem > 8 > 8 > 8 > 8 > 8 > 8
Piperacillin/Tazobactam > 64/4 > 64/4 > 64/4 > 64/4 > 64/4 > 64/4
Table 1. Demographic characteristics and clinical outcomes of patients with KPC-KPN isolated
 Patient PFGE Sex/age Underlying Comorbid LOS Previous Source  Antibiotic Leukocyte Clinical Clinical
 num-  pat- (years) condition condition (days)  antibiotics, infection  treatment urine/  signs outcome
 ber terns     (days)   urinary of sepsis   
          catheter   
          removal 
          (Yes/No)
 1 A M/46 Acute  20 Ceftriaxone (14)  Blood Polymyxin B _ Yes Death, 
    abdominal    Metronidazole     related to
    perforation   (14)     infection
 2 B F/69 CNS tumor Cancer 23 - Urine Ciprofloxacin > 106 No  Cured
          No
 3 A F/54 UTI CHF,  3  Urine Ceftriaxone 6 x 105  Yes Death, not 
     COPD, RF  -   Yes  related to  
            infection
 4 C M/59 CNS cancer Cancer,  78 Meropenem (49) CNS Meropenem - Yes Death not
     steroids   Vancomycin (64) catheter    related to
       Cefepime (11)       infection
 5 A M/89 Infected  Chronic 33 Ciprofloxacin  Urine Cefepime 4 x 105 No Cured
    foot ulcer arterial  (21)   Yes
     insufficiency
 6 A F/72 CNS tumor Cancer 18 Cefepime (12) Urine Cefepime 16 x 104 No Cured
     steroids     Yes
M, male; F, female; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary 
disease; LOS, length of stay prior to culture positive; RF, renal failure; UTI, urinary tract infection.
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Among the six KPC-KPN isolates, three PFGE patterns 
were observed and denominated patterns A, B and C. Four 
isolates were clonally related (pattern A), while two isolates 
were not, with one of them isolated from a patient who had 
been hospitalized in a different institution. 
CASE REPORTS
Clinical case 1
In April 2008, a 46 year-old man was submitted to an explor-
atory laparotomy due to perforated peptic ulcer and sent to 
the ICU for recovery. The patient had dehiscence of the sur-
gical wound and was reoperated. After receiving ceftriaxone 
2 g twice daily, and metronidazol 500 mg three times a day 
for 14 days, the patient developed Klebsiella pneumoniae 
bloodstream infection associated with septic shock, and an-
tibiotic was changed for piperacillin-tazobactam. This path-
ogen was resistant to ertapenem, but susceptible to imipen-
em by the MicroScan. This fi nding drew our attention to 
the possibility of a KPC-KPN. Three days after the isolation 
of KPC-KPN, the Hodge’s test confi rmed the production of 
a carbapenemase, and polymyxin B 15.000 UI/kg/day was 
initiated. No clinical response was observed and the patient 
deceased nine days later. 
Clinical case 2
In May 2008, a 69 year-old woman was admitted for an elec-
tive surgical resection of a central nervous system (CNS) tu-
mor. In the post-operatory, the patient was admitted on the 
neurosurgery ICU, and remained in this unit for 11 days. Af-
ter this period, the patient was sent to the neurosurgery ward, 
and fi ve days later, she presented an urosepsis. The patient 
was not receiving any antibiotics and intravenous ciproﬂ oxa-
cin 400 mg twice daily was initiated. Urine culture confi rmed 
the pure growth of K. pneumoniae (> 105 colony unit forms), 
susceptible to ciproﬂ oxacin but resistant to ertapenem. The 
urethral catheter was removed and ciproﬂ oxacin therapy was 
maintained for seven days. The patient showed a complete 
recovery and was discharged from the hospital 38 days later. 
Clinical case 3
A 54 year-old woman was admitted to the ICU with signals and 
symptoms of septic shock due to a urinary tract infection. She 
was started on ventilatory support and noradrenaline and cef-
triaxone 1 g twice daily were prescribed. The patient had a his-
tory of being hospitalized in another hospital 15 days before the 
current clinical manifestation. After three days, a K. pneumo-
niae (> 106 UFC) resistant to ertapenem, imipenem and mero-
penem was isolated from the urine culture. At that time, the 
patient was asymptomatic and not dependent on vasopressive 
drugs or mechanical ventilation. Since the patient had an excel-
lent clinical response, ceftriaxone treatment was completed in 
the internal medicine ward. However, the patient died due to 
cardiac and respiratory failure after 27 days of hospitalization.
Clinical case 4
In June 2008, a 59 year-old man was admitted to hospital 
for a CNS tumor resection. In the 5th PO day, the patient 
had a surgical complication with a secondary bowel perfo-
ration by the ventriculo-peritoneal shunt. A fecal peritonitis 
was diagnosed and the patient was submitted to abdomi-
nal surgery. The ventriculo-peritoneal shunt was removed 
and an external ventricular shunt (EVS) was placed on. 
A K. pneumoniae secondary meningitis occurred three days 
after the EVS placement. This pathogen was susceptible to 
broad-spectrum cephalosporins and cefepime 2 g three times 
a day was empirically prescribed and kept until the 11th day 
of therapy, when an Acinetobacter baumannii was isolated 
from the spinal ﬂ uid during a routine culture. The EVS was 
replaced and cefepime therapy was stopped. Meropenem 
(2 g three times a day) was initiated and despite the isolation 
of A. baumannii, vancomycin 1 g twice daily was added to 
the antimicrobial regimen because the patient had under-
gone many surgical procedures during his hospitalization. 
After 49 days of vancomycin and meropenem therapy, a 
K. pneumoniae resistant to imipenem, meropenem and er-
tapenem was recovered from the CNS device. The neurosur-
gery team considered the K. pneumoniae as a contaminant 
because it was not recovered from his cerebrospinal ﬂ uid. 
The antimicrobial therapy was not modifi ed, and the patient 
died fi ve months later due to a respiratory infection.
Clinical case 5 
In August 2008, an 89 year-old male with chronic arterial 
insuffi ciency was admitted to the vascular surgery ward for 
treatment of an infected right foot ulcer. The patient was 
treated with ciproﬂ oxacin 400 mg twice daily, and submitted 
to surgical treatment due to common iliac artery occlusion. 
In the 32nd day of hospitalization, the patient had signals 
and symptoms suggestive of urinary tract infection; cipro-
ﬂ oxacin therapy was replaced by cefepime 2 g twice daily. 
Three days later, the results of urine culture became avail-
able and showed the growth of a KPC-KPN (> 106 CFU/mL). 
Since the patient had become asymptomatic, cefepime ther-
apy was kept and the patient was discharged from the hospi-
tal after completing seven days of therapy.
Clinical case 6 
A 72 year-old female patient with previous history of CNS 
tumor was taken unconscious to the emergency unit. Despite 
of the patient’s option for not receiving surgical treatment, 
tumor resection was performed with the family consent. 
The patient was admitted to the ICU, where she received 
prolonged mechanical ventilation and urinary catheteriza-
tion. She received antibiotic therapy with cefepime 2 g twice 
daily due to a tracheobronchitis. She was extubated four 
days later due to rapid clinical improvement. A urine culture 
was collected before urinary catheter removal in spite of no 
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infection evidence. A KPC-KPN (> 105 CFU) was recovered 
from urine and considered just a colonizer since the patient 
had no clinical manifestations of urinary tract infection. The 
patient did not receive any antibiotics and was discharged 
one day later from our hospital.
DISCUSSION
We described microbiological features and clinical out-
comes of six patients from whom KPC-KPN strains were 
fi rstly isolated in our institution. KPC-KPN represents a real 
challenge, since microbiological detection of this resistant 
phenotype might be tricky. In addition, a few therapeutic 
options are available for treatment of such infections, and 
are basically restricted to polymyxins and tigecycline.3 
In our study, a urinary catheter was placed in all four 
patients from whom KPC-KPN strains were isolated from 
urine. All of these patients also showed elevated leukocyte 
count in urine. It has been reported that the risk of devel-
oping bacteriuria increased by 5% for each additional day 
of urinary catheterization and 50% of the patients had ac-
quired bacteriuria by the tenth day of catheterization.13 The 
distinction between urinary colonization and infection is 
diffi cult because many times patients hospitalized in ICUs 
are sedated or unconscious and are not able to provide 
clinical information about his/her symptoms. Just one of 
the four patients colonized/infected by KPC-KPN strains 
was conscious and confi rmed the symptoms suggestive of 
infection. This patient was successfully treated with cipro-
ﬂ oxacin guided by the antimicrobial susceptibility testing 
results. Two other patients were also successfully treated 
with broad-spectrum cephalosporins in spite of no reliable 
in vitro activity of these agents against KPC-KPN strains.14 
We believe that these patients were infected by KPC-KPN 
strains because there was a resolution of clinical symptoms 
after introduction of the antimicrobial regimen. The suc-
cessful clinical outcomes experienced by the patients treated 
with beta-lactam antibiotics have been previously reported15 
but the degree to which the antibiotic treatment contribut-
ed to these outcomes is diffi cult to ascertain. Good clinical 
response to antibiotics with no in vitro activity might have 
been achieved by the increased antimicrobial concentration 
in the urine. In addition, most of the patients had the urine 
catheter removed, and this is of crucial importance for a suc-
cessful outcome.14 Antimicrobial treatment was not modi-
fi ed because the Hodge test’s fi nal result was available only 
after the third day of beta-lactam therapy, when the patients 
have already had a favorable clinical outcome. 
The patient reported in the clinical case 1 had a severe KPC-
KPN infection with a fatal outcome that could be attributed to 
an inadequate empiric therapy with piperacillin/tazobactam, a 
delay in the introduction of polymyxin as well as the low dose 
regimen of the later agent. Therapy was only changed three days 
after the isolation of Gram-negative bacilli in the blood culture. 
Currently, the therapeutic options for highly resistant, 
carbapenemase-producing organisms are limited. Poly-
myxin B and tigecycline both seem to have reliable ef-
ficacy.3 Polymyxin is a compound developed decades ago 
and previously abandoned due to its toxicity. It has been 
resurrected because it is the only available therapeutic op-
tion for treatment of some pan-resistant Gram-negatives 
infections.16 Tigecycline is a novel extended-spectrum 
minocycline derivative, approved by the American Food 
and Drug Administration (FDA) for treatment of com-
plicated skin, intra-abdominal infections and communi-
ty-acquired pneumonia, but not for bloodstream and/or 
urinary infections.17 Although KPC-producing isolates 
show higher tigecycline MICs than those of wild type bac-
terial isolates, tigecycline possesses potent in vitro activ-
ity against these pathogens.18 Clinical data also supports 
efficacy of tigecycline for treating MDR Gram-negative 
infections in body sites where tigecycline does not reach 
therapeutic levels when habitual dosage regimens are pre-
scribed.19 In these situations, the use of combined therapy 
and/or higher doses of tigecycline are critical for maximal 
therapeutic effectiveness.20 This would be specially useful 
in patients with infections due to pathogens with reduced 
susceptibility to polymyxin, such as those presented in 
the clinical cases 4 and 6. 
Although our study describes a small number of hetero-
geneous patients at a single institution, our fi ndings should 
provide early clinical experience in treating KPC-KPN in-
fections in Brazil. Our results also underscore the impor-
tance of implementation of strict infection control measures 
to limit their dissemination, since four isolates were clonally 
related suggesting a patient-to-patient transmission in our 
institution. 
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